Achtung !! Am Montag wirds extrem spannend, zumal 4:30 p.m. Eastern Time Quartalzahlen und 5:00 p.m ein conference call stattfindet. Kann sich jeder von uns mit einwählen und lauschen
Press Release XenoPort to Release Fourth Quarter Financial Results on February 22, 2010 SANTA CLARA, Calif., Feb 10, 2010 (BUSINESS WIRE) -- XenoPort, Inc. ( Nasdaq : XNPT) announced today that it will release its fourth quarter financial results on February 22, 2010 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day. A replay of the call will be available for one week following the event. To access the conference call via the Internet, go to http://www.XenoPort.com. Please join the call at least 15 minutes prior to the start to ensure time for any software downloads that may be required.
To access the live conference call via phone, dial 1-888-275-3514. International callers may access the live call by dialing 706-679-1417. The reference number to enter the call is 56561397.
The replay of the conference call may be accessed that same day after 8:00 p.m. Eastern Time, via the Internet, at http://www.XenoPort.com, or via phone at 1-800-642-1687 for domestic callers, or 706-645-9291 for international callers. The reference number to enter the replay of the call is 56561397.
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. XenoPort is collaborating with Astellas Pharma Inc. and GlaxoSmithKline (GSK) to develop its lead product candidate, XP13512. Astellas has recently filed a new drug application (NDA) with the Pharmaceuticals and Medical Device Agency in Japan for XP13512 as a potential treatment for restless legs syndrome. The U.S. Food and Drug Administration is currently reviewing GSK's NDA for XP13512, which is known as Horizant(TM) (gabapentin enacarbil) in the United States, as a potential treatment for moderate-to-severe primary restless legs syndrome. XenoPort's product candidates are being studied for the potential treatment of restless legs syndrome, gastroesophageal reflux disease, migraine headaches, neuropathic pain, spasticity and Parkinson's disease. ----------- Jeder muss seine eigenen Entscheidungen treffen ! Letzter Vortag Veränderung 0,501 € 0,002 € +24.950,00% 0,553 € 0,003 € +18.333,33% |